Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samira Rasaneh

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Biomedizinische Technik. Biomedical Engineering|July 7, 2015
The possibility of using magnetic nanoparticles to increase the therapeutic efficiency of Herceptin antibodySamira Rasaneh, Maryam-Rahele Dadras
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|May 5, 2015
Activity estimation in radioimmunotherapy using magnetic nanoparticlesSamira Rasaneh, Hossein Rajabi, Fariba Johari Daha
Soudni Lekarstvi|April 24, 2014
Relationship between the stature and the length of long bones measured from the X-rays; modified trotter and gleser formulae in iranian population: A preliminary reportMohammadreza Farsinejad, Samira Rasaneh, Nasim Zamani, et al.
Applied Radiation and Isotopes : Including Data, Instrumentation and Methods for Use in Agriculture, Industry and Medicine|June 12, 2010
Toxicity of trastuzumab labeled 177Lu on MCF7 and SKBr3 cell linesSamira Rasaneh, Hossein Rajabi, Mohammad Hossein Babaei, et al.
Nuclear Medicine and Biology|November 9, 2010
177Lu labeling of Herceptin and preclinical validation as a new radiopharmaceutical for radioimmunotherapy of breast cancerSamira Rasaneh, Hossein Rajabi, Mohammad Hossein Babaei, et al.
Iranian Journal of Pharmaceutical Research : IJPR|October 6, 2017
Development of DOTA-Rituximab to be Labeled with <sup>90</sup>Y for Radioimmunotherapy of B-cell Non-Hodgkin LymphomaFariba Johari Doha, Siyavash Rahmani, Pedram Rikhtechi, et al.
Nuclear Medicine and Biology|May 9, 2009
Radiolabeling of trastuzumab with 177Lu via DOTA, a new radiopharmaceutical for radioimmunotherapy of breast cancerSamira Rasaneh, Hossein Rajabi, Mohammad Hossein Babaei, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Biomedizinische Technik. Biomedical Engineering|July 7, 2015
The possibility of using magnetic nanoparticles to increase the therapeutic efficiency of Herceptin antibodySamira Rasaneh, Maryam-Rahele Dadras
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|May 5, 2015
Activity estimation in radioimmunotherapy using magnetic nanoparticlesSamira Rasaneh, Hossein Rajabi, Fariba Johari Daha
Soudni Lekarstvi|April 24, 2014
Relationship between the stature and the length of long bones measured from the X-rays; modified trotter and gleser formulae in iranian population: A preliminary reportMohammadreza Farsinejad, Samira Rasaneh, Nasim Zamani, et al.
Applied Radiation and Isotopes : Including Data, Instrumentation and Methods for Use in Agriculture, Industry and Medicine|June 12, 2010
Toxicity of trastuzumab labeled 177Lu on MCF7 and SKBr3 cell linesSamira Rasaneh, Hossein Rajabi, Mohammad Hossein Babaei, et al.
Nuclear Medicine and Biology|November 9, 2010
177Lu labeling of Herceptin and preclinical validation as a new radiopharmaceutical for radioimmunotherapy of breast cancerSamira Rasaneh, Hossein Rajabi, Mohammad Hossein Babaei, et al.
Iranian Journal of Pharmaceutical Research : IJPR|October 6, 2017
Development of DOTA-Rituximab to be Labeled with <sup>90</sup>Y for Radioimmunotherapy of B-cell Non-Hodgkin LymphomaFariba Johari Doha, Siyavash Rahmani, Pedram Rikhtechi, et al.
Nuclear Medicine and Biology|May 9, 2009
Radiolabeling of trastuzumab with 177Lu via DOTA, a new radiopharmaceutical for radioimmunotherapy of breast cancerSamira Rasaneh, Hossein Rajabi, Mohammad Hossein Babaei, et al.
Pageof 1